Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 449

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 449
---
 changes. 

Risks Related to our Common Stock

Our stock price is subject to volatility, and your investment may suffer a decline in value.

The market prices for securities of biopharmaceutical companies have in the past been, and are likely to continue in the future to be, very volatile. The market price of our common stock is subject to substantial volatility depending upon many factors, many of which are beyond our control, including:

•our ability to expand or retain our HEPLISAV-B vaccine market share;

•impact of COVID-19 or other respiratory or seasonal vaccination initiatives on our HEPLISAV-B vaccine, CpG 1018 adjuvant, or other product revenue;

•progress or results of any of our clinical trials or regulatory or manufacturing efforts, in particular any announcements regarding the progress or results of our planned trials and BLA filing and communications, from the FDA or other regulatory authorities;

•our ability to receive timely regulatory approval for our product candidates;

•our ability to establish and maintain collaborations for the development and commercialization of our product candidates;

•our ability to raise additional capital to fund our operations, to the extent needed;

•technological innovations, new commercial products or drug discovery efforts and preclinical and clinical activities by us or our competitors;

•changes in our intellectual property portfolio or developments or disputes concerning the proprietary rights of our products or product candidates;

•our ability to obtain component materials and successfully enter into manufacturing relationships for our products or product candidates or establish manufacturing capacity on our own;

•our ability to establish and maintain licensing agreements for intellectual property necessary for the development of our product candidates;

•changes in government regulations, general economic conditions or industry announcements;

•changes in the structure of healthcare payment systems;

•issuance of new or changed securities analysts’ reports or recommendations;

•accumulations of our common stock or other public actions by our stockholders and related market or investor perceptions and expectations, some of which may be speculative or short term in nature;

•actual or anticipated fluctuations in our quarterly financial and operating results; 

64

•the volume of trading in our common stock;

•investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance; and

•industry conditions and general financial, economic and political instability.

The stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Changes in the broader macroeconomic condition, including historically high inflation, changes